Showing 4341-4350 of 5957 results for "".
- VSP Vision Names New President of VSP Ventureshttps://modernod.com/news/kathleen-steele-named-president-of-vsp-ventures/2481370/VSP Vision announced that Kathleen Steele has been named president of VSP Ventures. In the role, Ms. Steele will lead the company’s business unit that provides care-focused choices for doctors of optometry looking for practice transition options. She will report to Kate Renwick-Es
- Johns Hopkins Researchers Explore Why Episodes of Low Blood Sugar Worsen Eye Disease in People with Diabeteshttps://modernod.com/news/johns-hopkins-researchers-explore-why-episodes-of-low-blood-sugar-worsen-eye-disease-in-people-with-diabetes/2481367/Researchers at Johns Hopkins Medicine say they have linked low blood sugar levels in people with diabetes with a molecular pathway that is turned on in oxygen-starved cells in the eye. The research, involving human and mouse eye cells and intact retinas grown in a low sugar (low glucose
- TFS HealthScience Acquires Appletree CI Group, Expanding Presence in Ophthalmologyhttps://modernod.com/news/tfs-healthscience-acquires-appletree-ci-group-expanding-into-ophthalmology/2481363/Contract research organization TFS HealthScience announced it has acquired Appletree CI Group, a CRO and global regulatory affairs service provider. Terms of the deal were not disclosed. The deal enhances TFS HealthScience's presence in the fields of op
- Three-Month Efficacy/Safety Data of SING IMT for AMD Publishedhttps://modernod.com/news/three-month-efficacysafety-data-of-sing-imt-for-amd-published/2481362/The first and largest single-surgeon case series to describe the short-term (3 months) safety and efficacy outcomes of the Smaller-Incision New-Generation Implantable Miniature Telescope (SING IMT) in patients with severe to profound bilateral central vision impairment due to advanced A
- Harrow Completes Acquisition of US Rights to Five Branded Ophthalmic Drugshttps://modernod.com/news/harrow-closes-acquisition-of-us-rights-to-ilevro-nevanac-vigamox-maxidex-and-triesence-and-will-begin-receiving-net-profit-payments-for-acquired-products/2481361/Harrow announced the closing of its previously announced acquisition with Novartis of the exclusive US commercial rights to five branded ophthalmic products: Ilevro, Nevanac, Vigamox, Maxidex, and Triesence. In December, Harrow announced it had 
- Study: Maintaining the Enzyme ACE2 in the Gut May Prevent Diabetic Blindnesshttps://modernod.com/news/type-1-diabetes-maintaining-the-enzyme-ace2-in-the-gut-prevents-diabetic-blindness/2481360/A new study from the University of Alabama at Birmingham shows that the progressive damage to blood vessels in the light-sensitive tissue at the back of the eye may be due to a leaky small intestine that weakens the barrier between gut bacteria and the blood system. The study publi
- CXL Ophthalmics Appoints Jonathan Talamo, MD, as Chair of the Boardhttps://modernod.com/news/cxl-ophthalmics-appoints-jonathan-talamo-md-as-chair-of-the-board/2481355/CXL Ophthalmics announced that Jonathan Talamo, MD, has been appointed as its new Chair of the Board of Directors. Dr. Talamo has served as a Board member for the company since 2020. CXLO is developing a minimally-invasive treatment for ectatic corneal disease. The company's Ep
- Bausch + Lomb Acquires AcuFocushttps://modernod.com/news/bausch-lomb-acquires-acufocus/2481353/Bausch + Lomb announced it has acquired AcuFocus, maker of the IC-8 Apthera IOL. Financial terms of the deal were not disclosed. The moves bolsters Bausch + Lomb's cataract surgery portfolio. AcuFocus' IC-8 was approved by the FDA in July
- CORE Names Its “Top 10 of 2022” Scientific Papershttps://modernod.com/news/core-names-its-top-10-of-2022-scientific-papers/2481351/Ahead of the first global eye care conference of the year, the Centre for Ocular Research & Education (CORE) has announced its “Top 10 of 2022” publications list, designating works of significant value to clinicians, researchers, educators, and manufacturers. The papers
- Glaukos Announces Positive Results for iDose TR Exchange Trial, Highlighting Favorable Safety and Tolerabilityhttps://modernod.com/news/glaukos-announces-positive-results-for-idose-tr-exchange-trial-highlighting-favorable-safety-and-tolerability/2481346/Glaukos announced positive results for a prospective, multicenter clinical trial designed to evaluate the safety of the surgical exchange procedure for iDose TR (travoprost intraocular implant) in subjects who had previously been administered an iDose TR in the phase